Tags

Type your tag names separated by a space and hit enter

D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia.
Eur Neuropsychopharmacol. 2009 Jun; 19(6):440-50.EN

Abstract

Phencyclidine (PCP) produces cognitive deficits of relevance to schizophrenia in animal models. The aim was to investigate the efficacy of the D(1)-like receptor agonist, SKF-38393, to improve PCP-induced deficits in the novel object recognition (NOR) and operant reversal learning (RL) tasks. Rats received either sub-chronic PCP (2 mg/kg) or vehicle for 7 days, followed by a 7-day washout. Rats were either tested in NOR or the RL tasks. In NOR, vehicle rats successfully discriminated between novel and familiar objects, an effect abolished in PCP-treated rats. SKF-38393 (6 mg/kg) significantly ameliorated the PCP-induced deficit (P<0.01) an effect significantly antagonised by SCH-23390 (0.05 mg/kg), a D(1)-like receptor antagonist (P<0.01). In the RL task sub-chronic PCP significantly reduced performance in the reversal phase (P<0.001); SKF-38393 (6.0 mg/kg) improved this PCP-induced deficit, an effect antagonised by SCH-23390 (P<0.05). These results suggest a role for D(1)-like receptors in improvement of cognitive function in paradigms of relevance to schizophrenia.

Authors+Show Affiliations

Bradford School of Pharmacy, University of Bradford, Bradford, West Yorkshire BD71DP, UK. s.l.mclean@bradford.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19268547

Citation

McLean, Samantha L., et al. "D(1)-like Receptor Activation Improves PCP-induced Cognitive Deficits in Animal Models: Implications for Mechanisms of Improved Cognitive Function in Schizophrenia." European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, vol. 19, no. 6, 2009, pp. 440-50.
McLean SL, Idris NF, Woolley ML, et al. D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol. 2009;19(6):440-50.
McLean, S. L., Idris, N. F., Woolley, M. L., & Neill, J. C. (2009). D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, 19(6), 440-50. https://doi.org/10.1016/j.euroneuro.2009.01.009
McLean SL, et al. D(1)-like Receptor Activation Improves PCP-induced Cognitive Deficits in Animal Models: Implications for Mechanisms of Improved Cognitive Function in Schizophrenia. Eur Neuropsychopharmacol. 2009;19(6):440-50. PubMed PMID: 19268547.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. AU - McLean,Samantha L, AU - Idris,Nagi F, AU - Woolley,Marie L, AU - Neill,Joanna C, Y1 - 2009/03/05/ PY - 2008/09/22/received PY - 2009/01/22/revised PY - 2009/01/27/accepted PY - 2009/3/10/entrez PY - 2009/3/10/pubmed PY - 2009/6/26/medline SP - 440 EP - 50 JF - European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology JO - Eur Neuropsychopharmacol VL - 19 IS - 6 N2 - Phencyclidine (PCP) produces cognitive deficits of relevance to schizophrenia in animal models. The aim was to investigate the efficacy of the D(1)-like receptor agonist, SKF-38393, to improve PCP-induced deficits in the novel object recognition (NOR) and operant reversal learning (RL) tasks. Rats received either sub-chronic PCP (2 mg/kg) or vehicle for 7 days, followed by a 7-day washout. Rats were either tested in NOR or the RL tasks. In NOR, vehicle rats successfully discriminated between novel and familiar objects, an effect abolished in PCP-treated rats. SKF-38393 (6 mg/kg) significantly ameliorated the PCP-induced deficit (P<0.01) an effect significantly antagonised by SCH-23390 (0.05 mg/kg), a D(1)-like receptor antagonist (P<0.01). In the RL task sub-chronic PCP significantly reduced performance in the reversal phase (P<0.001); SKF-38393 (6.0 mg/kg) improved this PCP-induced deficit, an effect antagonised by SCH-23390 (P<0.05). These results suggest a role for D(1)-like receptors in improvement of cognitive function in paradigms of relevance to schizophrenia. SN - 1873-7862 UR - https://www.unboundmedicine.com/medline/citation/19268547/D_1__like_receptor_activation_improves_PCP_induced_cognitive_deficits_in_animal_models:_Implications_for_mechanisms_of_improved_cognitive_function_in_schizophrenia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-977X(09)00030-3 DB - PRIME DP - Unbound Medicine ER -